Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin L Masters

Showing results (441-450 of 776) with videos related to

Pageof 78
Sort By:
Molecular Psychiatry|August 30, 2021
The Amyloid-β Pathway in Alzheimer's DiseaseHarald Hampel, John Hardy, Kaj Blennow, et al.
International Psychogeriatrics|July 23, 2013
The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCIKarra D Harrington, Yen Ying Lim, Kathryn A Ellis, et al.
Alzheimer'S Research & Therapy|April 17, 2021
Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methodsJames D Doecke, Cindy Francois, Christopher J Fowler, et al.
Journal of Alzheimer'S Disease : JAD|May 16, 2018
Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission TomographyBelinda M Brown, Stephanie R Rainey-Smith, Vincent Dore, et al.
JAMA Psychiatry|January 29, 2015
Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort studyRobert H Pietrzak, Yen Ying Lim, Alexander Neumeister, et al.
The Journal of Biological Chemistry|January 26, 2005
Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicityAnna K Tickler, Danielle G Smith, Giuseppe D Ciccotosto, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 5, 2017
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE studyVictor L Villemagne, Christopher C Rowe, Kevin J Barnham, et al.
The Medical Journal of Australia|March 16, 2011
Advances in structural and molecular neuroimaging in Alzheimer's diseaseKathryn A Ellis, Christopher C Rowe, Cassandra E I Szoeke, et al.
The Australian and New Zealand Journal of Psychiatry|June 22, 2019
A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?Dhamidhu Eratne, Samantha M Loi, Nirbaanjot Walia, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Plasma p-tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinicDhamidhu Eratne, Matthew Kang, Charles B Malpas, et al.
Pageof 78

Showing results (441-450 of 776) with videos related to

Sort By:
Pageof 78
Molecular Psychiatry|August 30, 2021
The Amyloid-β Pathway in Alzheimer's DiseaseHarald Hampel, John Hardy, Kaj Blennow, et al.
International Psychogeriatrics|July 23, 2013
The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCIKarra D Harrington, Yen Ying Lim, Kathryn A Ellis, et al.
Alzheimer'S Research & Therapy|April 17, 2021
Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methodsJames D Doecke, Cindy Francois, Christopher J Fowler, et al.
Journal of Alzheimer'S Disease : JAD|May 16, 2018
Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission TomographyBelinda M Brown, Stephanie R Rainey-Smith, Vincent Dore, et al.
JAMA Psychiatry|January 29, 2015
Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort studyRobert H Pietrzak, Yen Ying Lim, Alexander Neumeister, et al.
The Journal of Biological Chemistry|January 26, 2005
Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicityAnna K Tickler, Danielle G Smith, Giuseppe D Ciccotosto, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 5, 2017
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE studyVictor L Villemagne, Christopher C Rowe, Kevin J Barnham, et al.
The Medical Journal of Australia|March 16, 2011
Advances in structural and molecular neuroimaging in Alzheimer's diseaseKathryn A Ellis, Christopher C Rowe, Cassandra E I Szoeke, et al.
The Australian and New Zealand Journal of Psychiatry|June 22, 2019
A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?Dhamidhu Eratne, Samantha M Loi, Nirbaanjot Walia, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Plasma p-tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinicDhamidhu Eratne, Matthew Kang, Charles B Malpas, et al.
Pageof 78